key: cord-0914861-b2x4r4dp
authors: Xiao, Jie; Zhang, Ben; Su, Zhengchen; Liu, Yakun; Shelite, Thomas R.; Chang, Qing; Wang, Pingyuan; Bukreyev, Alexander; Soong, Lynn; Jin, Yang; Ksiazek, Thomas; Gaitas, Angelo; Rossi, Shannan L.; Zhou, Jia; Laposata, Michael; Saito, Tais B.; Gong, Bin
title: EPAC regulates von Willebrand factor secretion from endothelial cells in a PI3K/eNOS-dependent manner during inflammation
date: 2020-09-04
journal: bioRxiv
DOI: 10.1101/2020.09.04.282806
sha: 3a5ab6904064d91a493f2e43e173938949bb0e9a
doc_id: 914861
cord_uid: b2x4r4dp

Coagulopathy is associated with both inflammation and infection, including infection with the novel SARS-CoV-2 (COVID-19). Endothelial cells (ECs) fine tune hemostasis via cAMP-mediated secretion of von Willebrand factor (vWF), which promote the process of clot formation. The exchange protein directly activated by cAMP (EPAC) is a ubiquitously expressed intracellular cAMP receptor that plays a key role in stabilizing ECs and suppressing inflammation. To assess whether EPAC could regulate vWF release during inflammation, we utilized our EPAC1-null mouse model and revealed an increased secretion of vWF in endotoxemic mice in the absence of the EPAC1 gene. Pharmacological inhibition of EPAC1 in vitro mimicked the EPAC1−/− phenotype. EPAC1 regulated TNFα-triggered vWF secretion from human umbilical vein endothelial cells (HUVECs) in a phosphoinositide 3-kinases (PI3K)/endothelial nitric oxide synthase (eNOS)-dependent manner. Furthermore, EPAC1 activation reduced inflammation-triggered vWF release, both in vivo and in vitro. Our data delineate a novel regulatory role of EPAC1 in vWF secretion and shed light on potential development of new strategies to controlling thrombosis during inflammation. Key Point PI3K/eNOS pathway-mediated, inflammation-triggered vWF secretion is the target of the pharmacological manipulation of the cAMP-EPAC system.

Coagulopathy is associated with both inflammation and infection, including infection with the novel SARS-CoV-2 (COVID- 19) . Endothelial cells (ECs) fine tune hemostasis via cAMP-mediated secretion of von Willebrand factor (vWF), which promote the process of clot formation. The exchange protein directly activated by cAMP (EPAC) is a ubiquitously expressed intracellular cAMP receptor that plays a key role in stabilizing ECs and suppressing inflammation. To assess whether EPAC could regulate vWF release during inflammation, we utilized our EPAC1-null mouse model and revealed an 

Coagulopathy is associated with both severe inflammation and infections, including the coronavirus-induced disease 2019 (COVID-19) 1-5 . To maintain vascular patency, vascular endothelial cells (ECs) adjust the balance between blood coagulation, bleeding, and fibrinolysis on their luminal surfaces via complicated mechanisms [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Accumulating evidence has suggested an extensive crosstalk between coagulation and inflammation, whereby inflammation leads to activation of coagulation, and coagulation also considerably affects inflammatory activity [17] [18] [19] . Systemic infectious diseases can activate ECs and propagate immune responses and inflammation in the blood vessels, increasing the risk of microthrombosis, which has been documented in lethal and non-lethal COVID-19 cases 1-5 .

One of fundamental mechanisms that EC employs to regulate coagulation is by secreting membrane-associated adhesive glycoprotein von Willebrand factor (vWF) in an elongated secretory organelle, Weibel-Palade body (WPBs) [20] [21] [22] [23] . vWF is synthesized in ECs and megakeryocytes and its main function is to directly promote clot formation via capturing platelets and chaperoning clotting factor VIII [22] [23] [24] . Current research has confirmed that vWF is not only a plasma glycoprotein known for its clotting role, but also a modulator on inflammatory responses [25] [26] [27] [28] [29] . As one of two principal cargos, vWF can determine the assembly of WPB, which contains a variety of other molecules involved in inflammation 21 and intercellular communication 30 , including angiopoietin-2 27 , IL-8 31 , and eotaxin-3 31 , and intra/extracellular vesicle membrane protein CD63 30 . WPB egress is associated with the secretion of its two major protein constituents, vWF and P-selectin, from EC in response to various stimuli 6, 23, 32 . P-selectin is a neutrophil and monocyte adhesion molecule important in the initiation of inflammation 18, 33 . Collectively, regulating endothelial secretion of vWF from WBP may modulate not only thromboembolic complications, but also inflammation.

Endothelial secretion of vWF in WBP is under tight control 24, 34, 35 . In general, endothelial WPBs become responsive to exogenous stimuli that increase intracellular Ca 2+ levels or the second messenger cAMP [36] [37] [38] . The effects of cAMP are transduced by two ubiquitously expressed intracellular cAMP receptors, protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC). EPAC proteins are a family of intracellular sensors for cAMP. In mammals, the EPAC protein family contains two members: EPAC1 and EPAC2 39,40 . Both EPAC isoforms function by responding to increased intracellular cAMP levels in a PKA-independent manner and act on the same immediate downstream effectors, the small G proteins Rap1 and Rap2 40,41 . EPAC1 is the major isoform in ECs, and Rap activation by EPAC1, but not EPAC2, contributes to the effects of cAMP-elevating hormones on endothelial barrier functions [42] [43] [44] . Growing evidence has revealed that the cAMP-EPAC signaling axis plays a regulatory role in suppressing inflammation 45, 46 . The first identified non-cAMP EPAC1 specific agonist (ESA), I942, was shown to suppress IL-6 signaling and inflammatory gene expression in ECs in response to inflammatory stimuli 46 , suggesting EPAC1 playing an endothelial functionstabilizing role during inflammation 43,47 . In ECs, it has been documented that cAMP provokes the secretion of vWF via the cAMP-PKA pathway 21, 35 . We have reported that cAMP-EPAC are involved in hemostasis by driving endothelial luminal surface expressions of tissue plasminogen activator receptor annexin A2, thereby promoting vascular fibrinolysis both in vivo and in vitro 48 . However, whether cAMP-EPAC is involved in regulating endothelial vWF secretion during inflammation remains to be elucidated. In contrast to the documented EC function-stabilizing effects of the EPACs 43,47 , an in vitro study 49 showed human umbilical vein endothelial cells (HUVECs) increase release of vWF after a short exposure to an EPAC-specific cAMP analog, which can be hydrolyzed by serum esterases 50,51 and requires to work in starvation media 52 .

In the present study, taking advantage of our EPAC1-knockout (KO) mouse model 7 , the EPACspecific inhibitor (ESI) 53 , and the non-cAMP ESA 52 , we defined the role(s) of EPAC1 in regulation of vWF secretion from ECs in response to inflammatory stimulus both in vivo and in vitro. We found that the EPAC1 gene deletion elevated the secretion of vWF in endotoxemic mice. Inactivation of EPAC1 potentiated the tumor necrosis factor-α (TNFα)-triggered vWF release. ESA had the capability to reduce the secretion of vWF during inflammation both in vivo and in vitro. Mechanism studies indicated that activation of host phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) / endothelial nitric oxide synthase (eNOS) can attenuate the efficacy of ESI and limit vWFs from secretion during inflammation.

The mouse experiments performed for this study were carried out in accordance with National Institutes of Health, United States Dept. of Agriculture, and UAMS Division of Laboratory Animal Medicine and Institutional Animal Care and Use Committee (IACUC) guidelines. The protocol supporting this study was approved by the UTMB IACUC.

We employed a mouse model of endotoxemia that consisted of intraperitoneal injection of a high dose of E. coli LPS (5 mg/kg) (Escherichia coli serotype O111:B4; Sigma, MO, USA). For more information, please see Supplemental data.

Atomic force microscopy (AFM) to measure cell surface expression of target protein As described previously 54 , the biomechanical properties of P-selectin or CD63 at the cell surface were studied using an AFM system (Flex-AFM, Nanosurf AG, Liestal, Switzerland) that utilized relevant antibody-functionalized AFM probes. For more information, please see Supplemental data.

Statistical significance was determined using Student's t-test or one-way analysis of variance (ANOVA). Results were regarded as significant if two-tailed P values were < 0.05. All data are expressed as mean ± standard error (SE) of the mean.

In testing the constitutive plasma levels of vWF, we observed no difference between WT and KO mice ( Figure 1A) . The difference in vWF mRNA expression between these two types of mice was not significant ( Figure 1B) . To further explore the EPAC1 function on inflammation-triggered vWF expression and secretion in vivo, WT and KO mice were treated with LPS (5 mg/kg/d, i.p) or PBS for 2 hrs. The results showed that exposure to LPS increased the plasma levels of vWF; compared to the LPS-treated WT counterparts, the plasma levels of vWF were higher in LPS-treated KO mice (p < 0.01) ( Figure 1A) . However, the changes of vWF mRNA expressions in lung and liver tissue were not significant (Figures 1B) . LPS-treated KO mice showed thrombosis, and microthrombi were detected in lungs, brains, and livers of LPS-treated KO mice, but were almost absent in LPS-treated WT mice (Table 1) ( Figure S1A ).

Since vWF performs critical functions in primary hemostasis, a tail bleeding time test was conducted 55 . The bleeding time of LPS-treated KO mice was shorter than that of LPS-treated WT mice ( Figure 1C) . The total blood loss, assessed by its hemoglobin content, corresponded closely with the observed bleeding time of LPS-treated KO and WT mice ( Figure 1D) . Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were also detected. There was no significant difference among the groups ( Figure S1B ).

In conclusion, EPAC1-KO mice show a higher level of plasma vWF than WT mice in the state of inflammation, in which microthrombi progression was detected.

TNFα can regulate vWF expression 56 . We observed that the vWF level was increased in the culture media of HUVECs treated with rTNFα (50 ng/ml) for 4 hrs (p < 0.05) (Figure 2A) . To determine the effect of EPAC1 inhibition on EC secretion of vWF in response to inflammatory mediators, we treated HUVECs with NY173, a novel ESI 53 to inhibit EPAC1 in HUVECs. NY173 did not affect the viability of HUVECs while the concentration was 1μM to 5μM ( Figure S2A ). NY173(2 μM) had little impact on the vWF secretion from HUVECs (Figures S2B and S2C) . We found that pretreatment with NY173 (2 μM) for 24 hrs enhanced rTNFα-triggered vWF secretion into media (p < 0.01) ( Figure   2A ). Western Blots were used to detect the intracellular vWF protein expression, which was reduced in the rTNFα-treated group (p <0.05), and more significantly reduced in the ESI NY173+rTNFαtreated group, vs the rTNF only group (p < 0.01) ( Figure 2B ).

ESA I942, the first identified non-cyclic nucleotide small molecule with agonist properties towards EPAC1 showed very little agonist action towards EPAC2 or protein kinase A (PKA) 57, 58 . While the concentration of I942 was among 5μM to 50μM, it had little influence on the viability of HUVECs ( Figure S2A ). I942 (30 μM) had no effect on the vWF secretion from HUVECs (Figures S2B and   S2C ). In this study, HUVECs were pretreated with I942 (30 μM) for 24 hrs before exposure to rTNFα (50 ng/mL) for 4 hrs. ESA I942 (30 μM) down-regulated the secretion of vWF from rTNFα-treated HUVECs (p < 0.05) (Figure 2A) . Compared to rTNFα-treated group, a significantly elevated intracellular vWF expression was observed in I942+rTNFα treated group ( Figure 2B) . Combined with the result that ESI NY173 upregulates rTNFα-induced vWF release, this demonstrates that EPAC1 modulates vWF secretion from HUVECs and the non-cAMP ESA has the capacity to limit vWF from secretion during inflammation.

To illuminate the effect of EPAC1 on the WPB secretion during inflammation, vWF-IF was used to detect intracellular WPBs 59, 60 . HUVECs were pre-treated with NY173 (2 μM) or I942 (30 μM) for 24 hrs followed by rTNFα (50 ng/ml) for 4 hrs. IF-labeled intracellular WPBs showed rod or spot shapes in the fluorescent images (arrowheads in Figure 3A ). Image J analysis showed that the number of WPBs in rTNFα group was decreased significantly, suggesting that WPBs release could be triggered by rTNFα ( Figure 3B ). However, ESA I942 limits the rTNFα-stimulated exocytosis of WPBs, while ESI NY173 enhances such egress ( Figure 3B ).

In addition to vWF and P-selectin, CD63 was detected in WPBs 61 . To further assess whether WPBs exocytosis during inflammation can be modulated by EPAC1, HUVECs were treated with NY173 or I942 for 24 hrs followed by rTNFα (50 ng/ml) for 4 hrs. Increased expressions of P-selectin in plasma membranes from cells treated with rTNFα+NY173 were observed compared with rTNFα groups ( Figure 3C ). The same result was observed in the expression of CD63 ( Figure 3D ). Inverse effects of ESA were showed by observing decreased P-selectin and CD63 expressions in plasma membranes from rTNFα+I942-treated cells (Figure 3 ).

To further validate these results in living cells, we used AFM to quantify the distribution of CD63 and P-selectin on surface of HUVECs. AFM has been used to determine the expression levels of cell surface proteins by measuring the binding affinity of specific protein-protein interactions with nano force spectroscopy 7 . In our study, we measured the specific unbinding force during rupture of the interaction between the antigen (CD63 or P-selectin) expressed at the apical surface of live HUVECs and the antibody-coated AFM cantilever probe. Interactions between antibodies on the AFM cantilever and cell surface antigens caused large adhesion forces, which were quantified by the deflection signal during separation of the cantilever from the cell. The result showed that the adhesion forces in NY173+rTNFα group were stronger than those in single rTNFα group (Figure 4) , consistent with increased P-selectin and CD63 antigen expression on the apical surface of a single live HUVEC.

These data suggest that pharmacological inhibition or activation of EPAC1 affects the expression of P-selectin and CD63 on cell membranes and modulate the inflammatory-triggered exocytosis of WPBs in HUVECs.

We next assessed whether P-selectin is only the molecular cargo of WPBs or correlated with vWF closely in EC. Previous studies have shown that P-selectin can bind to D′D3 domains of vWF, which is crucial for P-selectin recruitment 62 . Moreover, D′D3 domains of vWF have already been implicated in vWF storage and multimerization 63, 64 . These studies suggest that P-selectin is more than a cargo protein of WPBs. Understanding the complex molecular spatial relationship of protein-protein physical interaction is essential for accomplishing comprehensive knowledge of the functional outcome 65 . In this study, PLA was used to detect P-selectin/vWF spatial proximities and CD63/vWF spatial proximities in HUVECs during inflammation, as we described 65 . Both the P-selectin-vWF proximities and CD63-vWF proximities could be detected in HUVECs. More importantly, pharmacological manipulation of EPAC1 could regulate the P-selectin-vWF proximities (Figures 5A,

HUVECs were increased in I942 group, while NY173 inducing an opposite effect ( Figure 5D ). The results of PLA suggest that protein-protein proximal interactions exist between vWF and P-selectin or CD63, and that the P-selectin-vWF spatial proximity can be modulated by EPAC1.

The nitric oxide (NO) system has a wide range of biological properties in maintaining vascular homeostasis. It is known that the TNFα effect on the NO message is associated with down-regulation of endothelial nitric oxide synthase (eNOS) 66, 67 , and that the lack of eNSO likely contributes to the release of vWF 68 . We therefore examined whether rTNFα decreased eNOS expression, and whether it then promoted vWF release from HUVECs. We found that rTNFα reduced the eNOS mRNA but not iNOS mRNA levels in HUVECs (p < 0.01) ( Figure 6A and Figure S3 ). L-NAME hydrochloride, a NOS inhibitor, showed a non-significant trend to promote rTNFα-induced vWF secretion.

Nevertheless, rTNFα-triggered vWF secretion could be markedly reversed by DETA NONOate, an NO donor ( Figure 6B) . These results suggested that TNFα promote vWF secretion through downregulating the expression of eNOS in HUVECs.

Next, we examined whether the regulatory role of EPAC on rTNFα-triggered vWF secretion was eNOS depended, by comparing pretreatment with NY173 solely, or together with NO donor before challenged with rTNFα. RT-qPCR showed that NY173(2μM) had no effect on the mRNA level of eNOS ( Figure S3A ), but the eNOS mRNA level was further decreased in the NY173+rTNFα group than in rTNFα only group (p < 0.05) ( Figure 6A) . However, iNOS did not made such a change ( Figure  S3B ). Furthermore, the effect of NY173 on TNF-triggered vWF secretion can be neutralized by NO donor (p < 0.01) ( Figure 6B) .

Activation of EPAC leads to a PI3K-dependent PKB activation 69 

To further evaluate the effects of EPAC1 on the vWF secretion during inflammation in vivo, WT mice were pretreated with I942 (5 mg/kg/d, i.p.×3) or PBS, followed by LPS injection (5 mg/kg/d, i.p.×1) or PBS. ELISA was performed to detect the plasma vWF concentrations. The results showed that I942 treatment significantly reduced the plasma vWF levels of endotoxemic mice compared with the control group (Figure 7) , suggesting targeting EPCA1 with ESA can potentially control coagulopathy during inflammation.

Using in vivo and in vitro models, we demonstrated that EPAC1, as a documented EC functionstabilizing effector, regulated the vWF secretion from ECs triggered by inflammation. Deletion of the EPAC1 gene or pharmacologically inactivation of EPAC1 significantly facilitated inflammationinduced vWF secretion. On the contrary, activation of EPAC1 by ESA attenuated the vWF secretion in ECs under inflammation. ESI increased P-selectin expression in cell plasma membrane and affected the protein space proximity of P-selectin-vWF. Activation of PI3K or increased NO expression in NY173-treated HUVECs significantly reduced the efficacy of NY173 in promoting inflammationtriggered vWF secretion. Furthermore, by utilizing the endotoxemic mouse model, we observed that ESA (I942) reduced the inflammation-induced vWF secretion in vivo. These in vivo and in vitro data unravel a novel regulatory role for EPAC1 in vWF secretion from ECs. Importantly, the cAMP-EPAC signaling axis can be exploited as a potential target for the development of compounds to control vWF secretion triggered by inflammation.

The hallmark of acute and chronic inflammation is the widespread activation of ECs which provokes excessive vWF secretion from the EC storage pool by WPB exocytosis 73 . vWF is secreted via three pathways. They are regulated secretion, basal secretion, and constitutive secretion 23, 34 . The first two types of vWF-secretion pathways occur from WPBs and deliver highly multimerized vWF, but the third pathway releases vWF that has not been packaged into WPBs and, thus, has not undergone high levels of multimerisation 38 . In contrast to continuously secreting vWF from basal pathway, the release of vWF from the regulated pathway occurs only following stimulation of ECs with an appropriate agonist, providing the endothelium with the means to react to its microenvironment by finely tuning the rate of release. Thus, controlling WPB exocytosis from ECs is an important way to regulate the concentration of vWF in plasma under inflammatory stress 73, 74 .

It has been proved that treatment of HUVECs with I942, which represents an effective tool to probe the function of cellular EPAC1, leads to alterations in the expression of a wide variety of genes associated with vascular function. In particular, I942 suppresses the expression of the proinflammatory adhesion molecules in HUVECs 75 . Upon an inflammatory trigger, ECs are activated, prompting the massive release of WPBs that contain vWF and P-selectin 76 . We observed rTNFα-induced vWF secretion was increased in ESI pretreatment group, while ESA had the opposite effect. In addition to these in vitro results, EPAC-KO endoxemic mice had higher level of plasma vWF concentration than WT endoxemic mice. The results confirm that EPAC1 plays an important role in regulating inflammation-triggered vWF secretion. In contrast to our study, van Hooren, et al. reported that Me-cAMP-AM, an EPAC-specific cAMP analog, promotes release of vWF in HUVECs 49 . This discrepancy could be due to the different reagents and experimental conditions used in the in vitro experiments. In van Hooren's study, HUVECs were incubated with serum-free medium and supplemented with 1 μM Me-cAMP-AM for 60 mins. Since cAMP analogs are hydrolyzed by serum esterases 50,51 and requires to work in starvation media 52 , which restricts applications using primary ECs 47,77,78 . Moreover, evidence has been provided that most cAMP and cGMP analogs have multiple targets, including some EPAC specific analogs 77, 78 . In our study, we used the non-cyclic nucleotide ESA I942, to treat HUVECs for 24 hrs followed by rTNFα (50 ng/mL) for 4 hrs with complete medium.

We observed not only that ESA could inhibit vWF secretion triggered by inflammation, but also that ESI increased inflammation-triggered vWF secretion, in accordance with our observation during in vivo study using WT and KO mice.

To our knowledge, P-selectin, as a critical component of WPB, is anchored to the cell surface with the exocytosis of WPB following inflammatory stimulation of endothelial cells, and then provides binding sites for P-selectin ligands on the surface of circulating leukocytes 79, 80 . In the present study, P-selectin expression in the plasma membrane was elevated in rTNFα-treated HUVECs with ESI pretreatment, while the expressions were attenuated in that group with ESA pretreatment. The expressions of CD63, an essential cofactor to leukocyte recruitment by endothelial P-selectin 30 , were consistent with the change of P-selectin expressions. To our knowledge, this is the first report that EPAC regulates the expressions of P-selectin and CD63 on the cell membrane following inflammatory stimulation. Our results confirm the well-documented EC function-stabilizing effects of the EPACs from another perspective. Moreover, P-selectin, as a plasma marker of endothelial damage/dysfunction, is more than a cargo protein of the WPB. It has been reported that P-selectin binds to the D-D3 domains of VWF, which is not only crucial for P-selectin recruitment, but also be implicated in VWF storage 62, 63 . In our study, PLA was used to detect the spatial proximity between P-selectin and vWF, showing that pharmacological manipulation of EPAC1 can regulate P-selectin-vWF spatial proximities. The domains of vWF binding with P-selectin is critical to the storage of vWF.

Whether EPAC1 can manipulate the secretion of vWF by regulating the binding of P-selectin and vWF remains to be determined.

Under normal physiological conditions, ECs help prevent inflammation and inhibit clotting partly through the continuous production of nitric oxide 81, 82 . Viral infections, such as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), cause inflammatory cytokines release, EC injury, and NO production decline significantly 83 . TNFα can downregulate the eNOS expression in ECs 66 . Moreover, eNOS reduction leads to vWF release 68 . In this study, we also observed that rTNFα (50 ng/mL) incubating HUVECs for 4 hrs could potently decrease the eNOS mRNA expression. Using an NOS inhibitor or NO donor to regulate NO expression in HUVECs can manipulate the vWF secretion triggered by TNFα. It has been reported that EPAC activation can enhance the eNOS activity in ECs 84 .

Likewise, we observed that ESI NY173 further decreased the TNFα-induced eNOS mRNA reduction.

The NO donor, in turn, counteracted vWF secretion from HUVECs under the challenge of NY173 and TNFα. PI3Ks have been linked to an extraordinarily diverse group of cellular functions, including inflammation and coagulation [85] [86] [87] . An earlier study has shown that PI3K is critical in mediating the prothrombotic potential of ECs 88 . In vivo studies have shown that inhibition of PI3K strongly enhances the activation of EC, upregulates the LPS-induced coagulation and inflammation, and reduces the survival time of mice 87 . We incubated NY173-pretreated HUVECs with the PI3K-specific activators IRS-1 before challenging with rTNF-α. We found IRS-1 could dramatically reverse the effect of NY173 on inhibiting the eNOS expression and releasing of vWF. Activation of PI3K in NY173pretreated ECs significantly reduced the TNFα-induced inhibition of eNOS expression and vWF secretion, compared with the NY173-pretreated group that did not receive IRS-1. In support of the conclusion that EPAC mediates eNOS expression through the PI3K-Akt pathway from Namkoong et al 70 , we hypothesize that EPAC may regulate the rTNFα-trigger vWF release in a PI3K-eNOS dependent manner. Van Hoooren et al has reported that PI3K inhibitor LY294002 reduced epinephrine-induced release of vWF 89 . Comparing this study with ours, we found considerable differences in reagents and experimental conditions and the time-points observed in these two experiments were different. The incubation time of epinephrine and LY294002 in Van Hooren's study was ranged from 10 to 50 min, while our incubation time of PI3K activators was 24 hrs followed with 4 hrs of rTNFα-treatment time. In addition, epinephrine was used in Van Hooren's study to activate the vWF secretion. As we know, epinephrine not only stimulates vWF release through cAMP/EPAC pathway 37,49 , the cAMP/PKA pathway is another pathway that epinephrine regulates and affects vWF secretion [90] [91] [92] . EPAC and PKA might mediate the opposing effects on PKB regulation. Activation of EPAC leads to a PI3K-dependent PKB activation, while stimulation of PKA may inhibit PKB activity 69 .

Despite significant progress in the development of cAMP analogues as EPAC agonists 93 , the EPAC isoform selectivity of these cAMP analogues and their potential off-target effects on other molecules, such as cAMP phosphodiesterase, remain challenging 77, 78 . ESA I942, the first identified non-cyclic nucleotide small molecule with agonist properties towards EPAC1, and very little agonist action towards EPAC2 or PKA 57, 58 , has the potential to suppress proinflammatory cytokine signaling.

This reduces the risk of side effects associated with general cAMP-elevating agents that activate multiple response pathways in HUVECs 58 . In this study, it displayed a capability to exert its pharmacological effects in complete EC culture medium and it downregulated inflammation-triggered vWF secretion in HUVECs. Moreover, this report about in vivo application of I942 shows activation of EPAC1 in vivo significantly reduced the plasma vWF concentration in LPS-induced endotoxemic mice. Additional work is needed to further explore the possibility whether I942 can act as a novel therapeutic to regulate hemostasis.

Taken together, this study combined an in vitro primary human endothelial system with an in vivo mouse model to reveal the role of EPAC in inflammation-triggered vWF secretion. In vascular ECs, EPAC1 regulates inflammation-triggered vWF releasing in the PI3K/eNOS-dependent manner ( Figure S4) . ESA I942 has the capacity to limit vWFs from secretion during inflammation in vivo. 

a Near-serial cross sections were stained with the use of hematoxylin and eosin to detect thrombus in brains, lungs, hearts, livers, spleens, and kidneys by bright field microscopy. 6 scores: microthrombi could be detected in all the above organs; 5 scores: microthrombi could be detected in any of the above five organs; 4 scores: microthrombi could be detected in any of the above four organs; 3 scores: microthrombi could be detected in any of the above three organs; 2 scores: microthrombi could be detected in any of the above two organs; 1 score: microthrombi could be detected in only one of the above organs; 0 score: no microthrombi could be detected in any organs of the above. (C). The specific unbinding force measurements can be compiled for quantification of total P-selectin or CD63 expressions on certain areas on the living HUVECs surface. With P-selectin or CD63

antibody-coated cantilevers, the adhesion force was stronger in NY173+ TNFα-treated HUVECs, *P < 0.05. n=12 for each group. The results were expressed as fluorescence intensity per cell. n = 3 for each group. Normal mouse IgG-coated colloidal cantilever was employed during calibration of the AFM system before measuring the unbinding forces between Pselectin or CD63 antibody-coated cantilever and the cell (detail see Materials and Methods). (C) The specific unbinding force measurements can be compiled for quantification of total P-selectin or CD63 expressions on certain areas on the living HUVECs surface. With P-selectin or CD63 antibody-coated cantilevers, the adhesion force was stronger in NY173+ TNFα-treated HUVECs, *P < 0.05. n=12 for each group. 

COVID-19 and its implications for thrombosis and anticoagulation

Thromboinflammation and the hypercoagulability of COVID-19

COVID-19 and Acute Pulmonary Embolism in Postpartum Patient

Pulmonary embolism in patients with Covid-19 pneumonia

Exocytosis of Weibel-Palade bodies: how to unpack a vascular emergency kit

Exchange protein directly activated by cAMP plays a critical role in regulation of vascular fibrinolysis

Vascular Endothelial Cell Biology: An Update

Fibrinolysis and Inflammation in Venous Thrombus Resolution

Vimentin as an integral regulator of cell adhesion and endothelial sprouting

Regulation of fibrinolysis by S100A10 in vivo

Regulation of von-Willebrand Factor Secretion from Endothelial Cells by the Annexin A2-S100A10 Complex

Extravascular coagulation in hematopoietic stem and progenitor cell regulation

Exploring traditional and nontraditional roles for thrombomodulin

Activated protein C, protease activated receptor 1, and neuroprotection. Blood

The Biology of Annexin A2: From Vascular Fibrinolysis to Innate Immunity

Inflammation and coagulation

von Willebrand factor release and P-selectin expression is stimulated by thrombin and trypsin but not IL-1 in cultured human endothelial cells

Activation of coagulation after administration of tumor necrosis factor to normal subjects

Inflammation and haemostasis

Functional architecture of Weibel-Palade bodies

Physiological Roles of the von Willebrand Factor-Factor VIII Interaction

von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends

The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story

Active von Willebrand factor predicts 28-day mortality in patients with systemic inflammatory response syndrome

Inflammation, von Willebrand factor, and ADAMTS13. Blood

P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor

von Willebrand factor promotes leukocyte extravasation

von Willebrand factor regulation of blood vessel formation

CD63 is an essential cofactor to leukocyte recruitment by endothelial P-selectin

Weibel-Palade bodies in an endothelial cell line

Stimulated release of intraluminal vesicles from Weibel-Palade bodies

Selectins: initiators of leucocyte adhesion and signalling at the vascular wall

Basal secretion of von Willebrand factor from human endothelial cells

cAMP-induced secretion of endothelial von

Willebrand factor is regulated by a phosphorylation/dephosphorylation switch in annexin A2

Vasopressininduced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP

Epinephrine induces von Willebrand factor release from cultured endothelial cells: involvement of cyclic AMP-dependent signalling in exocytosis

Rickettsiae induce microvascular hyperpermeability via phosphorylation of VE-cadherins: evidence from atomic force microscopy and biochemical studies

Role of von Willebrand factor in the haemostasis

P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface

The Potential of a Novel Class of EPAC-Selective Agonists to Combat Cardiovascular Inflammation

Identification of a Novel

Effect of laminar shear stress on the distribution of Weibel-Palade bodies in endothelial cells

Real-time imaging of the dynamics and secretory behavior of Weibel-Palade bodies

CD63 is a component of Weibel-Palade bodies of human endothelial cells

P-selectin binds to the D'-D3 domains of von Willebrand factor in Weibel-Palade bodies

Critical independent regions in the VWF propeptide and mature VWF that enable normal VWF storage

Domains involved in multimer assembly of von willebrand factor (vWF): multimerization is independent of dimerization

Increased talin-vinculin spatial proximities in livers in response to spotted fever group rickettsial and Ebola virus infections

Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life

High serum TNF-alpha level in Type 2 diabetic patients with microangiopathy is associated with eNOS down-regulation and apoptosis in endothelial cells

Endothelial von Willebrand factor release due to eNOS deficiency predisposes to thrombotic microangiopathy in mouse aging kidney

Differential signaling of cyclic AMP: opposing effects of exchange protein directly activated by cyclic AMP and cAMPdependent protein kinase on protein kinase B activation

Forskolin increases angiogenesis through the coordinated cross-talk of PKA-dependent VEGF expression and Epac-mediated PI3K/Akt/eNOS signaling

Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin signaling by O-Linked beta-Nacetylglucosamine in 3T3-L1 adipocytes

Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A

The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy

Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease

The novel exchange protein activated by cyclic AMP 1 (EPAC1) agonist, I942, regulates inflammatory gene expression in human umbilical vascular endothelial cells (HUVECs)

von Willebrand factor and inflammation

Cyclic nucleotide analogs as probes of signaling pathways

Exchange proteins directly activated by cAMP (EPACs): Emerging therapeutic targets

Protein mobilities and P-selectin storage in Weibel-Palade bodies

Targeting selectins and selectin ligands in inflammation and cancer

Omentin protects against LPS-induced ARDS through suppressing pulmonary inflammation and promoting endothelial barrier via an Akt/eNOS-dependent mechanism

The relationship between inflammation and the anticoagulant pathway: the emerging role of endothelial nitric oxide synthase (eNOS)

Blood vessel injury may spur disease's fatal second phase

PKA and Epac activation mediates cAMP-induced vasorelaxation by increasing endothelial NO production

PI3K signalling in inflammation

The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications

PI3K-Akt pathway suppresses coagulation and inflammation in endotoxemic mice

Phosphatidylinositol-3,4,5-triphosphate-dependent Rac exchange factor 1 regulates epinephrine-induced exocytosis of Weibel-Palade bodies

Dynein-dynactin complex mediates protein kinase Adependent clustering of Weibel-Palade bodies in endothelial cells

Small GTP-binding protein Ral is involved in cAMPmediated release of von Willebrand factor from endothelial cells

Weibel-Palade bodies in endothelial cells

Structure-guided design of selective Epac1 and Epac2 agonists

ELISA was performed to analyze the plasma vWF concentrations in C57BL/6 mice which were treated with I942. Based on unpublished pharmacokinetic and toxicology data from another ongoing project to develop novel ESIs and ESAs, we used I942 at 5mg/kg/day (5 mg/kg/d, i.p.) for three days, then exposed to LPS (5 mg/kg, i.p.) or equal volume of PBS for 2hrs